Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Too many doctors fail to follow guidelines and to prescribe best treatments for heart patients

03.05.2005


Heart failure patients who are treated in accordance with established European guidelines do better than patients who are not, yet many doctors are still not adhering to the guidelines, according to pioneering research published today (Tuesday 3 May) in Europe’s leading cardiology journal, the European Heart Journal.



In the first large European study to look at the effect of prescribing practices on outcome in heart failure outpatients outside of a clinical trial[1], Professor Michel Komajda and colleagues investigated the way that 1,410 patients with mild to moderate heart failure were treated by 150 randomly selected cardiologists or cardiology departments in six European countries (France, Germany, Italy, The Netherlands, Spain and the UK). They measured how closely the patients’ treatment adhered to the guidelines issued by the European Society of Cardiology (ESC) for the use of the five most commonly used cardiac drugs: ACE-inhibitors[2], beta-blockers, spironolactone[3], diuretics and cardiac glycosides.

Prof Komajda, professor of cardiology at the Pitie-Salpetriere Hospital, Paris, France, and a specialist in heart failure, said: "We found that where doctors had treated their patients in accordance with the ESC guidelines, fewer patients had to be referred to the hospital due to deterioration of their heart failure or for cardiovascular symptoms, and there was a longer time before patients had to be readmitted to hospital because of their symptoms.


"However, the study showed that only 60% of patients were treated according to the ESC guidelines with ACE-inhibitors, beta-blockers or spironolactone – the three cardiac drugs for which there is the strongest evidence of benefit – and only 63% of patients were treated according to the guidelines for these three drugs plus the two other commonly used drugs, cardiac glycosides and diuretics.

"This means there is a high proportion of patients who are not receiving the best possible treatment for their condition, and who suffer worsening symptoms and even death as a result."

Patients in the MAHLER study[4] were aged 40 or over, with an average age of nearly 69. They were followed up for six months. The researchers found that while adherence to diagnosis guidelines was high at 74%, adherence to treatment guidelines was much lower, with large variations between the five different treatments; 85% of patients who needed them were prescribed ACE-inhibitors, 58% were given beta-blockers, 83% a diuretic agent, 52% a cardiac glycoside, and only 36% spironolactone.

When the researchers looked at the impact on outcome of the "big three" drugs (ACE-inhibitors, beta-blockers and spironolactone) they found that amongst patients who were treated with perfect adherence to the guidelines 6.7% and 11.2% were admitted to hospital with chronic heart failure (CHF) or a worsening of their cardiovascular (CV) symptoms respectively; this compared with figures of 9.7% and 15.9% respectively for moderate adherence and 14.7% and 20.6% for low adherence. These outcomes were independent of the severity of the disease, previous hospitalizations for CHF, or the presence of high blood pressure or diabetes.

"We found that adherence to treatment guidelines was independently and strongly correlated to outcome measured by rate of CHF or CV hospitalization and time to CV hospitalization," said Prof Komajda.

"We hope that these results will encourage cardiologists to ensure that they are familiar with, and adhere to, treatment guidelines. Integrated approaches, including nurses, dieticians, generalists and cardiologists, are needed in order to improve the management of chronic heart failure in clinical practice."

The researchers found there was plenty of room for improvement in the treatment of patients with heart failure. "Prescription of beta-blockers was observed in only half of the patients who should be receiving them, according to ESC guidelines. In contrast, a substantial proportion of our patients received cardiac glycosides despite the fact that this treatment is only recommended for symptomatic improvement. Overall, we found a high level of compliance to guidelines for ACE-inhibitors or diuretics, but a rather low level for beta-blockers, suggesting that there is still room for improving practice in Europe and that there is a need to develop training programmes to improve the quality of care for cardiac patients," said Prof Komajda.

A second paper[5] published in the EHJ today underlines the difficulty of persuading doctors to follow guidelines for treatment rather than relying on their own impressions of what might be best. In some cases patients who most need the best treatment receive the worst, according to the authors.

Professor Jean-Pierre Bassand, head of the department of cardiology at the University Hospital Jean Minjoz, Besançon, France, said: "It is obvious that guidelines improve outcome, so it is hard to understand why they are adopted so poorly. Surveys have shown that a limited number of doctors actually know about the existence of the guidelines, and even when they do know, they do not necessarily put them into medical practice. Sometimes physicians feel they are flooded by too much information and a plethora of guidelines."

He said there might be several reasons why doctors do not follow guidelines: economic constraints, lack of belief in the guidelines and "nihilism". "This means that treatments with life-saving potential are under-prescribed for a wide variety of reasons, valid or otherwise," he said.

"In addition, it would even appear that in acute coronary syndromes, there is an inverse relation between the severity of the patient’s symptoms when they are first seen by a doctor and the level of compliance with the guidelines; in other words, the more severe the initial symptoms, the less likely the patient is to receive the most efficacious treatment."

Prof Bassand and his co-authors said that guidelines issued by professional organisations such as the ESC should be regarded as pivotal educational tools that are used in continuing medical education programmes, which all doctors should attend so that they can update and extend their knowledge.

"Doctors at the national level, health authorities and industry need to work together to make sure that these guidelines are implemented, with incentives towards medial practices that apply evidence-based medicine in their treatment schemes. Otherwise, many patients will continue to suffer unnecessarily," said Prof Bassand.

1] Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. European Heart Journal. doi:10.1093/eurheartj/ehi251
[2] ACE-inhibitors are angiotensin-converting enzyme inhibitors.
[3] Spironolactone is a type of diuretic.
[4] MAHLER stands for Medical mAnagement of chronic Heart faiLure in Europe and its Related costs.
[5] Evidence-based vs. ’impressionist’ medicine: how best to implement guidelines. European Heart Journal. doi:10.1093/eurheartj/ehi262

Emma Mason | EurekAlert!
Further information:
http://www.escardio.org/

More articles from Health and Medicine:

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

nachricht A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>